Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides
First Claim
Patent Images
1. A complex between a Shigella flexneri polypeptide and a mammalian polypeptide as defined in columns 1 and 3 respectively of Table II.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to protein-protein interactions between Shigella polypeptides and mammalian polypeptides. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
50 Citations
20 Claims
- 1. A complex between a Shigella flexneri polypeptide and a mammalian polypeptide as defined in columns 1 and 3 respectively of Table II.
-
2. A complex between a Shigella flexneri polynucleotide encoding a polypeptide as defined in column 1 of Table II, and a mammalian polynucleotide encoding a polypeptide as defined in column 3 of Table II.
-
3. A recombinant host cell expressing a polynucleotide encoding a Shigella flexneri polypeptide as defined in column 1 of Table II and a polynucleotide encoding a mammalian polypeptide as defined in column 3 of Table II.
-
5. A method for selecting a modulating compound that inhibits or activates the protein-protein interactions between a Shigella flexneri polypeptide and a human placenta polypeptide in Table II comprising:
-
(a) cultivating a recombinant host cell on a selective medium containing a modulating compound and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors;
(i) wherein said first vector comprises a polynucleotide encoding a first hybrid polypeptide and a DNA bonding domain; and
(ii) wherein said second vector comprises a polynucleotide encoding a second hybrid polypeptide and an activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact; and
(b) selecting said modulating compound which inhibits the growth of said recombinant host cell. - View Dependent Claims (6, 16)
-
-
7. A SID®
- polypeptide comprising one of SEQ ID Nos. 216 to 416.
- View Dependent Claims (10, 11)
-
8. A SID®
- polynucleotide comprising one of SEQ ID Nos. 15 to 215.
- View Dependent Claims (9, 12, 13, 14, 15, 18)
-
17. A pharmaceutical composition comprising a SID®
- polypeptide of SEQ ID Nos. 216 to 416 and a pharmaceutically acceptable carrier.
-
19. A protein chip comprising a Shigella flexneri polypeptide of SEQ ID NOS. 1 to 7 or a mammalian polypeptide of Column 3, Table II.
-
20. A record comprising all or part of the data set forth in Tables I and II.
Specification